Table 3.
Correlation analysis between the lncRNA GAS5 expression and the clinicopathological features of melanoma patients
| Clinicopathological features | Cases (n = 75) | Expression of lncRNA GAS5 | p value | |
|---|---|---|---|---|
| Low expression (n = 58, 77.33%) | High expression (n = 17, 22.67%) | |||
| Gender | ||||
| Male | 28 | 21 (75) | 7 (25) | 0.710 |
| Female | 47 | 37 (78.72) | 10 (21.28) | |
| Age | ||||
| ≤ 65 years | 49 | 37 (75.51) | 12 (24.49) | 0.373 |
| > 65 years | 26 | 21 (80.77) | 5 (19.23) | |
| Breslow thickness | ||||
| ≤ 4 mm | 18 | 6 (33.33) | 12 (66.67) | 0.001 |
| > 4 mm | 57 | 52 (91.23) | 5 (8.77) | |
| Ulceration | ||||
| No | 22 | 7 (31.92) | 15 (68.18) | 0.001 |
| Yes | 53 | 51 (96.23) | 2 (3.77) | |
| Lymph node metastasis | ||||
| Negative | 24 | 12 (42.86) | 16 (57.14) | 0.001 |
| Positive | 51 | 45 (97.83) | 1 (2.17) | |
| TNM staging | ||||
| I | 19 | 4 (21.05) | 15 (78.95) | 0.0001 |
| II/III | 56 | 54 (96.43) | 2 (3.57) | |
Data were measurement data, expressed by mean ± standard deviation. Data comparison was analyzed by Chi square test. p < 0.05 indicates significant difference